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Sump syndrome can be managed effectively by biliary sphincterotomy and duct clearance. However, options for the management of sump syndrome in
patients who have not responded to sphincterotomy are limited. We report a case of refractory sump syndrome managed with endoscopic closure of the
choledochoduodenostomy using a cardiac septal occluder device.
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Choledochoduodenostomy (CDD) is occasionally performed in
conjunction with bile duct exploration for severe or refractory
choledocholithiasis.1,2 In some patients, food debris collects in the
portion of the common bile duct that is distal to the CDD. This may
cause pain and cholangitis and is termed “sump syndrome”. Usually
sump syndrome can be managed effectively by biliary sphincter-
otomy and duct clearance.3 However, options for management of
sump syndrome in patients who have not responded to sphinc-
terotomy are limited. We report a case of refractory sump syn-
dromemanagedwith endoscopic closure of the CDD using a cardiac
septal occluder device.
Case report
An 82-year-old Caucasian female underwent open common bile
duct exploration and CDD due to multiple large primary bile duct
stones that manifested many years after cholecystectomy. Unfor-
tunately, approximately 1 year after this surgery the patient began
to complain of right upper quadrant pain and fever and was found
to have abnormal liver biochemical tests. She then underwent a
total of six endoscopic retrograde cholangiopancreatography
(ERCPs) over the next 18 months with interventions including
biliary sphincterotomy, subsequent sphincterotomy extension,
large diameter papillary balloon dilation, and placement of multi-
ple biliary stents. Despite these interventions, she continued to
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material in the bile duct despite both the biliary oriﬁce and CDD
being widely patent, compatible with refractory sump syndrome.
The patient was offered surgical correction (CDD closure and con-
version to hepaticojejunostomy) but she declined.
Attempted endoscopic closure of the CDD using a cardiac septal
occluder device was elected after thorough discussion with the
patient and informed consent. At ERCP, the CDDwas again observed
(Fig. 1A), with soft yellow stone material emanating from it. The
duodenoscope was passed to the second part of duodenum, where
a previously placed biliary stent was removed and the bile duct was
cleared of debris using a 15–18 mm extraction balloon (Fig. 1B). The
duodenoscope was withdrawn to the duodenal bulb and a 9–
12 mm biliary occlusion balloon was used to cannulate the CDD for
the purpose of sizing the oriﬁce. At 12 mm, the balloon met sig-
niﬁcant resistance to withdrawal across the CDD (Fig. 1C), but at
9 mm the balloon met only mild resistance. Based on this sizing, an
Amplatzer septal occluder device with a 10 mmwaist diameter was
selected. A 450 cm  0.89 mm super-stiff guidewire was passed via
the CDD into the bile duct (Fig. 1D), and eventually across the
papilla into the third portion of the duodenum. As the delivery
sheath for the septal occlude device was too short to pass through
the working channel of the duodenoscope, the scope was with-
drawn over the guidewire entirely out of the patient. The 8F, 90 cm
long delivery sheath was then passed over the wire using ﬂuoro-
scopic guidance until it just traversed the CDD into the bile duct
(Fig.1E). Next, the duodenoscopewas passed alongside the delivery
sheath to the duodenal bulb. The septal occluder device was then, Oklahoma City, OK, USA
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Fig. 1. Choledochoduodenostomy (CDD) closure using a cardiac septal occluder device.
Gastrointestinal Intervention 2013 2(2), 121–123122advanced inside the delivery sheath. With the tip of the device
positioned in the bile duct, the guide wire was removed. The in-
ternal 20 mm disk was then deployed in the bile duct. Traction was
applied to the delivery system, tenting the bile duct toward the
duodenum. With the biliary disk well seated, the 18 mm duodenal
disk was deployed, with a 10 mmwaist occupying the CDD oriﬁce.
The device appeared well positioned on endoscopy (Fig. 1F) and
ﬂuoroscopy (Fig. 1G).
The patient did well immediately postprocedurally. Four
months after placement, she presented with signs and symptoms
compatible with bacterial cholangitis. At follow-up ERCP, the septal
occluder device was found to be properly positioned endoscopi-
cally (Fig. 1H) and ﬂuoroscopically (Fig. 1I). A 15 mm occlusion
balloon could be trolled past the biliary disk with minimal resis-
tance in the patient’s diffusely dilated bile duct. Minimal sludge and
no stones were swept from the biliary tree. The bile duct was
explored using an ultraslim gastroscope. The biliary disk was
properly seated and contained only a thin ﬁlm of yellow stone
material. The patient was treated with oral antibiotics and quickly
recovered. Ursodeoxycholic acid 500 mg twice daily was pre-
scribed, as wasmaintenance ciproﬂoxacin at a dose of 250mg twice
daily during the ﬁrst week of each month, both with the intent of
potential prophylaxis against further instances of cholangitis.
Over the ensuing 2.5 years, the patient largely did well from a
clinical standpoint. She developed symptoms and signs suggestiveof mild bacterial cholangitis approximately twice a year during this
time. This was typically managed with a short course of intrave-
nous antibiotics, with success. No further ERCPs were undertaken.
The patient died from causes unrelated to her biliary issues (com-
plications of cardiac disease) 3 years after the septal occluder de-
vice was used to close the CDD.Discussion
Sump syndrome is occasionally not resolved by biliary sphinc-
terotomy, leading to a management dilemma. In patients who
refuse surgery or in whom surgery is contraindicated, endoscopic
management may represent the best therapeutic option. Refractory
sump syndrome must be distinguished from stenosis of the CDD,
which may present similarly. To date, very few endoscopic treat-
ment approaches have been reported for refractory sump syn-
drome. A single German case report described the successful use of
the Amplatzer septal occluder to close a CDD.4 The Amplatzer
septal occluder (AGAMedical Corporation, Golden Valley, MN, USA)
is a proprietary device constructed of Nitinol wires shaped into two
ﬂat disks and a central waist (Fig. 2). The device has been used in
humans since 1997 to repair cardiac atrial septal defects. It is
available in a variety of disk and waist diameters, and is capable of
closing defects up to 40 mm in diameter. Aside from its initial
Fig. 2. Amplatzer septal occluder. (A) Prior to deployment (front view). (B) Prior to deployment (lateral view). (C) Fully deployed (lateral view).
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oesophageal and bronchopulmonary ﬁstulae.5,6
In our patient, the device appeared to successfully close the
CDD. On follow-up ERCP there was only minimal sludge in her bile
duct, whereas on all prior examinations the bile duct was noted to
contain copious amounts of solid organic material. This technical
success appears to have translated into partial clinical success.
Unfortunately our patient developed mild clinical cholangitis
approximately twice a year in the 3 years following CDD occlusion.
However, this represented a marked decrease in the frequency and
severity of episodes of cholangitis.
In conclusion, in cases of refractory sump syndrome, a cardiac
septal occluder may be used to occlude the CDD, preventing further
food entry into the bile duct. However, the device wires may be
lithogenic, and the problem of infected bile remains. The role for
ursodeoxycholic acid and prophylactic antibiotics to address these
issues empirically remains uncertain and, as such, this procedure is
best considered experimental at this time.Conﬂict of interest
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